
## IN THE CLAIMS

## Please amend the claims as follows:

9. (twice amended) A method of treating a neoplastic condition or toxicity in a subject associated with an alteration in sphingolipid metabolism comprising administering an effective amount of a furrousin or a furrousin analog thereof of the formula:

voads on analogue Lumonisin analogue But hot



wherein the spacer group is selected from the group consisting of alkyl (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>), hydroxyalkyl (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>); Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O), CO<sub>2</sub>, C(O)NH, and C(O)NQ, wherein Q is an alkyl (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>); W is selected from the group consisting of no substituent, H, alkyl (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>) or halo), C(O)(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H (where n= 1 - 6), C(O) (CH<sub>2</sub>)<sub>n</sub> CW'<sub>2</sub> CO<sub>2</sub> H, where W' is selected independently from H, alkyl (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>) or halo), and (CH<sub>2</sub>)<sub>n</sub> CO<sub>2</sub> H, wherein n= 1 - 6; X is selected from the group consisting of H, methyl, CH<sub>2</sub> OH (and esters thereof), CH<sub>2</sub> NQ'<sub>2</sub> (where Q' is selected independently from H, alkyl (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>); and V and Y are independently selected from the group consisting of H or OH (and esters thereof).



12. (twice amended) The method of Claim 9, wherein the fumonisin or fumonisin analog is administered in an amount between 5 and 500 mg.